Your browser doesn't support javascript.
loading
Partial Splenic Embolization in a Patient with Hemophilia A and Severe Thrombocytopenia: A Case Report.
Nakamura, Tomofumi; Uchiba, Mitsuhiro; Nakata, Hirotomo; Mizumoto, Takao; Beppu, Toru; Matsushita, Shuzo.
Afiliación
  • Nakamura T; Department of Hematology, Rheumatology, and Infectious Diseases, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
  • Uchiba M; Department of Laboratory Medicine, Kumamoto University Hospital, Kumamoto 860-8556, Japan.
  • Nakata H; Department of Blood Transfusion and Cell Therapy, Kumamoto University Hospital, Kumamoto 860-8556, Japan.
  • Mizumoto T; Department of Hematology, Rheumatology, and Infectious Diseases, Kumamoto University Hospital, Kumamoto 860-8556, Japan.
  • Beppu T; Department of Surgery, National Hospital Organization Kumamoto Medical Center, Kumamoto 860-0008, Japan.
  • Matsushita S; Department of Surgery, Yamaga City Medical Center, Kumamoto 861-0501, Japan.
Hematol Rep ; 16(2): 185-192, 2024 Mar 26.
Article en En | MEDLINE | ID: mdl-38651448
ABSTRACT
We report a patient with hemophilia A who underwent partial splenic embolization (PSE) for severe thrombocytopenia secondary to portal hypertension-induced splenomegaly, resulting in a stable long-term quality of life. The patient was diagnosed with hemophilia A and unfortunately contracted human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) from blood products. He subsequently developed progressive splenomegaly due to portal hypertension from chronic HCV, resulting in severe thrombocytopenia. PSE was performed because he had occasional subcutaneous bleeding and needed to start interferon (IFN) and ribavirin (RBV) treatment for curing his HCV infection at that time. His platelet counts increased, and no serious adverse events were observed. Currently, he continues to receive outpatient treatment, regular factor VIII (FVIII) replacement therapy for hemophilia A, and antiretroviral therapy for HIV infection. Vascular embolization has been reported to be an effective and minimally invasive treatment for bleeding in hemophilia patients. PSE also provided him with a stable quality of life without the side effects of serious infections and thrombocytopenia relapses. We conclude that PSE is a promising therapeutic option for patients with hemophilia A.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Hematol Rep Año: 2024 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Hematol Rep Año: 2024 Tipo del documento: Article País de afiliación: Japón